TY - JOUR
T1 - Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation
AU - Krull, Kevin R.
AU - Zhang, Nan
AU - Santucci, Aimee
AU - Srivastava, Deo Kumar
AU - Krasin, Matthew J.
AU - Kun, Larry E.
AU - Pui, Ching Hon
AU - Robison, Leslie L.
AU - Hudson, Melissa M.
AU - Armstrong, Gregory T.
N1 - Funding Information:
This work was supported by the grant CA138988 (G.T.A.), the Cancer Center Support (CORE) grant CA21765 from the National Cancer Institute, and by the ALSAC (American Lebanese Syrian Associated Charities). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
Publisher Copyright:
© 2013 by The American Society of Hematology.
PY - 2013/7/25
Y1 - 2013/7/25
N2 - Survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation therapy (CRT) are at risk for cognitive impairment, although whether impairment progresses with age into adulthood is unknown. We report change in intelligence for 102 adult survivors of childhood ALL (age range, 26.6-54.7 years) during a median interval of 28.5 years. Survivors demonstrated lower Performance intelligence (mean, 95.3; standard deviation, 16.5; P 5 .005) but not Verbal IQ (mean, 97.4; standard deviation, 15.44; P 5 .09) at initial testing. Verbal intelligence declined an average of 10.3 points (P < .0001) during the follow-up interval with no decline in Performance intelligence. Decline was associated with current attention problems (P 5 .002) but not gender, CRT dose, age at CRT exposure, or years between testing. Results suggest long-term survivors of childhood ALL treated with CRT are at risk for progressive decline in verbal intellect, which may be driven by attention deficits. This trial was registered at clinicaltrials.gov as no. NCT00760656.
AB - Survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation therapy (CRT) are at risk for cognitive impairment, although whether impairment progresses with age into adulthood is unknown. We report change in intelligence for 102 adult survivors of childhood ALL (age range, 26.6-54.7 years) during a median interval of 28.5 years. Survivors demonstrated lower Performance intelligence (mean, 95.3; standard deviation, 16.5; P 5 .005) but not Verbal IQ (mean, 97.4; standard deviation, 15.44; P 5 .09) at initial testing. Verbal intelligence declined an average of 10.3 points (P < .0001) during the follow-up interval with no decline in Performance intelligence. Decline was associated with current attention problems (P 5 .002) but not gender, CRT dose, age at CRT exposure, or years between testing. Results suggest long-term survivors of childhood ALL treated with CRT are at risk for progressive decline in verbal intellect, which may be driven by attention deficits. This trial was registered at clinicaltrials.gov as no. NCT00760656.
UR - http://www.scopus.com/inward/record.url?scp=84886884561&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886884561&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-03-487744
DO - 10.1182/blood-2013-03-487744
M3 - Article
C2 - 23744583
AN - SCOPUS:84886884561
SN - 0006-4971
VL - 122
SP - 550
EP - 553
JO - Blood
JF - Blood
IS - 4
ER -